BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fenebrutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fenebrutinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07161258-11333@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Fenebrutinib: Phase 2 readout est. (NCT07161258)
DESCRIPTION:Fenebrutinib\, phase 2\, Multiple Sclerosis.\nStudy: A Pharmaco
 kinetics (PK)\, Pharmacodynamics (PD)\, Safety and Tolerability Study of F
 enebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis 
 (RMS)\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fenebrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07161258
URL:https://assetmemo.bio/drug/fenebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937852-11333@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Fenebrutinib: Phase 3 readout est. (NCT07937852)
DESCRIPTION:Fenebrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participant
 s With Multiple Sclerosis (MS)\nEstimated primary completion: 30 November 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/fenebrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079378
 52
URL:https://assetmemo.bio/drug/fenebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
